Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1982 2
1983 4
1984 1
1985 1
1986 2
1987 4
1988 2
1989 5
1990 11
1991 11
1992 8
1993 15
1994 15
1995 14
1996 24
1997 16
1998 15
1999 17
2000 20
2001 17
2002 12
2003 17
2004 23
2005 24
2006 17
2007 9
2008 17
2009 16
2010 12
2011 6
2012 9
2013 8
2014 6
2015 11
2016 9
2017 5
2018 11
2019 3
2020 9
2021 9
2022 19
2023 18
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

446 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
Bramante CT, Huling JD, Tignanelli CJ, Buse JB, Liebovitz DM, Nicklas JM, Cohen K, Puskarich MA, Belani HK, Proper JL, Siegel LK, Klatt NR, Odde DJ, Luke DG, Anderson B, Karger AB, Ingraham NE, Hartman KM, Rao V, Hagen AA, Patel B, Fenno SL, Avula N, Reddy NV, Erickson SM, Lindberg S, Fricton R, Lee S, Zaman A, Saveraid HG, Tordsen WJ, Pullen MF, Biros M, Sherwood NE, Thompson JL, Boulware DR, Murray TA; COVID-OUT Trial Team. Bramante CT, et al. N Engl J Med. 2022 Aug 18;387(7):599-610. doi: 10.1056/NEJMoa2201662. N Engl J Med. 2022. PMID: 36070710 Free PMC article. Clinical Trial.
The adjusted odds ratio for a primary event was 0.84 (95% confidence interval [CI], 0.66 to 1.09; P = 0.19) with metformin, 1.05 (95% CI, 0.76 to 1.45; P = 0.78) with ivermectin, and 0.94 (95% CI, 0.66 to 1.36; P = 0.75) with fluvoxamine. In prespecified secondary analyses …
The adjusted odds ratio for a primary event was 0.84 (95% confidence interval [CI], 0.66 to 1.09; P = 0.19) with metformin, 1.05 (95% CI, 0. …
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis.
Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, Zhou X, Wu Q, Zhang X, Feng Z, Wang M, Mao Q. Wen W, et al. Ann Med. 2022 Dec;54(1):516-523. doi: 10.1080/07853890.2022.2034936. Ann Med. 2022. PMID: 35118917 Free PMC article.
We conducted a meta-analysis to investigate the improvement in mortality or hospitalization rates and adverse events among COVID-19 patients with three new oral antivirals (including molnupiravir, fluvoxamine and Paxlovid). METHODS: We searched scientific and medical datab …
We conducted a meta-analysis to investigate the improvement in mortality or hospitalization rates and adverse events among COVID-19 patients …
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR. Cipriani A, et al. Lancet. 2018 Apr 7;391(10128):1357-1366. doi: 10.1016/S0140-6736(17)32802-7. Epub 2018 Feb 21. Lancet. 2018. PMID: 29477251 Free PMC article. Review.
In head-to-head studies, agomelatine, amitriptyline, escitalopram, mirtazapine, paroxetine, venlafaxine, and vortioxetine were more effective than other antidepressants (range of ORs 1.19-1.96), whereas fluoxetine, fluvoxamine, reboxetine, and trazodone were the least effi …
In head-to-head studies, agomelatine, amitriptyline, escitalopram, mirtazapine, paroxetine, venlafaxine, and vortioxetine were more effectiv …
Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19 : A Randomized Platform Trial.
Reis G, Dos Santos Moreira Silva EA, Medeiros Silva DC, Thabane L, de Souza Campos VH, Ferreira TS, Quirino Dos Santos CV, Ribeiro Nogueira AM, Figueiredo Guimaraes Almeida AP, Cançado Monteiro Savassi L, de Figueiredo Neto AD, Bitarães C, Cruz Milagres A, Diniz Callegari E, Campos Simplicio MI, Barra Ribeiro L, Oliveira R, Harari O, Wilson LA, Forrest JI, Ruton H, Sprague S, McKay P, Guo CM, Guyatt GH, Rayner CR, Boulware DR, Ezer N, Lee TC, McDonald EG, Bafadhel M, Butler C, Rodrigues Silva J, Dybul M, Mills EJ; TOGETHER Investigators. Reis G, et al. Ann Intern Med. 2023 May;176(5):667-675. doi: 10.7326/M22-3305. Epub 2023 Apr 18. Ann Intern Med. 2023. PMID: 37068273 Free PMC article. Clinical Trial.
BACKGROUND: Previous trials have demonstrated the effects of fluvoxamine alone and inhaled budesonide alone for prevention of disease progression among outpatients with COVID-19. OBJECTIVE: To determine whether the combination of fluvoxamine and inhaled budesonide w …
BACKGROUND: Previous trials have demonstrated the effects of fluvoxamine alone and inhaled budesonide alone for prevention of disease …
Evaluating fluvoxamine for the outpatient treatment of COVID-19: A systematic review and meta-analysis.
Deng J, Moskalyk M, Zuo QK, Garcia C, Abbas U, Ramaraju HB, Rayner D, Park YJ, Heybati K, Zhou F, Lohit S. Deng J, et al. Rev Med Virol. 2024 Jan;34(1):e2501. doi: 10.1002/rmv.2501. Epub 2023 Dec 26. Rev Med Virol. 2024. PMID: 38148036 Review.
In subgroup analyses, fluvoxamine reduced healthcare utilization in outpatients with BMI 30 kg/m(2) , but not in those with lower BMIs. While fluvoxamine offers potential benefits in reducing healthcare utilization, its efficacy may be most pronounced in high-risk p …
In subgroup analyses, fluvoxamine reduced healthcare utilization in outpatients with BMI 30 kg/m(2) , but not in those with lower BMI …
Fluvoxamine versus other anti-depressive agents for depression.
Omori IM, Watanabe N, Nakagawa A, Cipriani A, Barbui C, McGuire H, Churchill R, Furukawa TA. Omori IM, et al. Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006114. doi: 10.1002/14651858.CD006114.pub2. Cochrane Database Syst Rev. 2010. PMID: 20238342 Free PMC article. Review.
BACKGROUND: Fluvoxamine, one of the oldest selective serotonin reuptake inhibitors (SSRIs), is prescribed to patients with major depression in many countries. Several studies have previously reviewed the efficacy and tolerability of fluvoxamine for the treatment of …
BACKGROUND: Fluvoxamine, one of the oldest selective serotonin reuptake inhibitors (SSRIs), is prescribed to patients with major depr …
Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trial.
Farahani RH, Ajam A, Naeini AR. Farahani RH, et al. BMC Infect Dis. 2023 Mar 31;23(1):197. doi: 10.1186/s12879-023-08172-5. BMC Infect Dis. 2023. PMID: 37003990 Free PMC article. Clinical Trial.
RESULTS: We screened a total of 486 patients from March to June 2022. After 12 weeks, 42 patients receiving fluvoxamine and 43 patients receiving Placebo were evaluated for PCS. ...CONCLUSION: We concluded that taking fluvoxamine during active COVID-19 can reduce th …
RESULTS: We screened a total of 486 patients from March to June 2022. After 12 weeks, 42 patients receiving fluvoxamine and 43 patien …
Efficacy and tolerability of fluvoxamine in adults with social anxiety disorder: A meta-analysis.
Liu X, Li X, Zhang C, Sun M, Sun Z, Xu Y, Tian X. Liu X, et al. Medicine (Baltimore). 2018 Jul;97(28):e11547. doi: 10.1097/MD.0000000000011547. Medicine (Baltimore). 2018. PMID: 29995828 Free PMC article. Review.
OBJECTIVE: To investigate the efficacy and tolerability of fluvoxamine in adults with SAD, trials meeting the following criteria were identified: population: 18 years of age with a diagnosis of SAD; intervention: fluvoxamine; study design: placebo-controlled randomi …
OBJECTIVE: To investigate the efficacy and tolerability of fluvoxamine in adults with SAD, trials meeting the following criteria were …
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Sakuma K, Okuya M, Hatano M, Matsuda Y, Iwata N. Kishi T, et al. Mol Psychiatry. 2023 Jan;28(1):402-409. doi: 10.1038/s41380-022-01824-z. Epub 2022 Oct 17. Mol Psychiatry. 2023. PMID: 36253442 Free PMC article.
The meta-analysis comprised 34 studies (n = 9384, mean age = 43.80 years, and %females = 68.10%) on 20 antidepressants (agomelatine, amitriptyline, bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, mirta …
The meta-analysis comprised 34 studies (n = 9384, mean age = 43.80 years, and %females = 68.10%) on 20 antidepressants (agomelatine, amitrip …
Trial Sequential Analysis and Updated Meta-Analysis of Fluvoxamine on Clinical Deterioration in Adult Patients with Symptomatic COVID-19 Infection.
Yu CL, Carvalho AF, Thompson T, Tsai TC, Tseng PT, Hsu CW, Tu YK, Yang SN, Hsu TW, Yeh TC, Liang CS. Yu CL, et al. Int J Environ Res Public Health. 2023 Feb 24;20(5):4088. doi: 10.3390/ijerph20054088. Int J Environ Res Public Health. 2023. PMID: 36901099 Free PMC article. Review.
The effect of fluvoxamine lay within the futility boundary (i.e., lack of effect) when using a 30% relative risk reduction threshold. ...The role of fluvoxamine as a COVID-19 treatment cannot be justified....
The effect of fluvoxamine lay within the futility boundary (i.e., lack of effect) when using a 30% relative risk reduction threshold. …
446 results

Searches related to "fluvoxamine"